Largest pharmaceuticals by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Pfizer leads the 61 pharmaceuticals ranked by net assets, at SAR 324.4B, ahead of Johnson & Johnson (SAR 305.9B) and Sanofi (SAR 297.1B). Figures as of 18 Nov 2026, 14:31 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 61
- First
- PfizerSAR 324.4B
- Median
- SAR 3.3B
- Combined market value
- SAR 19.19T
- Countries
- 10
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | PfizerPFE · Health Care | SAR 324.4B | SAR 604.5B | SAR 106.05 | 0.66% down | 14% up | ||
| 2 | Johnson & JohnsonJNJ · Health Care | SAR 305.9B | SAR 2.49T | SAR 1,035.41 | 1.00% down | 38% up | ||
| 3 | SanofiSNY · Health Care | SAR 297.1B | SAR 426.1B | SAR 177.44 | 0.47% down | 4% down | ||
| 4 | Merck & CoMRK · Health Care | SAR 197.3B | SAR 1.31T | SAR 530.17 | 1.44% down | 51% up | ||
| 5 | Abbott LaboratoriesABT · Health Care | SAR 195.5B | SAR 680.2B | SAR 392.77 | 2.55% down | 17% down | ||
| 6 | AstraZenecaAZN · Health Care | SAR 182.5B | SAR 1.05T | SAR 674.73 | 1.28% down | 2% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | SAR 174.5B | SAR 257.2B | SAR 80.50 | 0.85% down | 54% up | ||
| 8 | NovartisNVS · Health Care | SAR 173B | SAR 1.11T | SAR 588.83 | 1.37% down | 25% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | SAR 117.2B | SAR 369.5B | SAR 3,571.44 | 0.59% down | 36% up | ||
| 10 | Novo NordiskNVO · Health Care | SAR 108B | SAR 663.8B | SAR 150.60 | 1.36% down | 17% down | ||
| 11 | Eli LillyLLY · Health Care | SAR 99.5B | SAR 4.7T | SAR 5,277.43 | 0.60% down | 35% up | ||
| 12 | GSKGSK · Health Care | SAR 81.5B | SAR 367.8B | SAR 183.50 | 0.62% down | 6% up | ||
| 13 | Vertex PharmaceuticalsVRTX · Health Care | SAR 70B | SAR 505.7B | SAR 1,994.43 | 0.47% down | 27% up | ||
| 14 | Bristol-Myers SquibbBMY · Health Care | SAR 69.3B | SAR 465.7B | SAR 227.84 | 1.04% down | 34% up | ||
| 15 | ViatrisVTRS · Health Care | SAR 55.2B | SAR 88.2B | SAR 76.90 | 0.24% up | 96% up | ||
| 16 | Royalty PharmaRPRX · Health Care | SAR 36.4B | SAR 147.6B | SAR 256.66 | 0.37% down | 78% up | ||
| 17 | Teva Pharmaceutical IndustriesTEVA · Health Care | SAR 29.7B | SAR 187.7B | SAR 160.82 | 0.62% up | 74% up | ||
| 18 | United TherapeuticsUTHR · Health Care | SAR 26.6B | SAR 92.9B | SAR 2,182.13 | 0.40% down | 23% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | SAR 24.6B | SAR 48.4B | SAR 96.81 | 0.15% down | 20% up | ||
| 20 | BioMarin PharmaceuticalBMRN · Health Care | SAR 22.8B | SAR 42.4B | SAR 218.65 | 0.38% down | 11% up | ||
| 21 | GrifolsGRFS · Health Care | SAR 21.9B | SAR 21.9B | SAR 32.15 | 0.70% down | 1% up | ||
| 22 | GenmabGMAB · Health Care | SAR 21.9B | SAR 119.3B | SAR 193.44 | 0.75% down | 70% up | ||
| 23 | Roivant SciencesROIV · Health Care | SAR 17B | SAR 105B | SAR 144.94 | 0.18% down | 90% up | ||
| 24 | BeOne MedicinesONC · Health Care | SAR 16.4B | SAR 174.3B | SAR 1,525.84 | 1.57% down | 17% up | ||
| 25 | Jazz PharmaceuticalsJAZZ · Health Care | SAR 16.2B | SAR 57.8B | SAR 900.62 | 0.25% down | 37% up | ||
| 26 | Dr. Reddy's LaboratoriesRDY · Health Care | SAR 15B | SAR 46.2B | SAR 55.40 | 0.20% down | 5% up | ||
| 27 | ZoetisZTS · Health Care | SAR 12.5B | SAR 125.5B | SAR 308.95 | 1.34% down | 29% down | ||
| 28 | AlkermesALKS · Health Care | SAR 6.8B | SAR 28.7B | SAR 171.08 | 0.35% up | 58% up | ||
| 29 | Ligand PharmaceuticalsLGND · Health Care | SAR 3.8B | SAR 22.2B | SAR 1,111.31 | 0.84% up | 43% up | ||
| 30 | Legend BiotechLEGN · Health Care | SAR 3.8B | SAR 11.8B | SAR 60.58 | 0.25% up | 42% down | ||
| 31 | Praxis Precision MedicinesPRAX · Health Care | SAR 3.3B | SAR 31.9B | SAR 1,142.48 | 0.16% down | 61% up | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | SAR 3B | SAR 78.1B | SAR 583.47 | 0.61% down | 66% down | ||
| 33 | Belite BioBLTE · Health Care | SAR 2.9B | SAR 24B | SAR 591.61 | 0.00% | 31% up | ||
| 34 | InsmedINSM · Health Care | SAR 2.8B | SAR 99.6B | SAR 453.87 | 0.71% down | 40% down | ||
| 35 | Spyre TherapeuticsSYRE · Health Care | SAR 2.7B | SAR 33.6B | SAR 353.31 | 0.41% up | 286% up | ||
| 36 | Summit TherapeuticsSMMT · Health Care | SAR 2.5B | SAR 31.2B | SAR 38.99 | 2.58% down | 36% down | ||
| 37 | TG TherapeuticsTGTX · Health Care | SAR 2.4B | SAR 35.4B | SAR 234.25 | 0.41% down | 107% up | ||
| 38 | Corcept TherapeuticsCORT · Health Care | SAR 2.4B | SAR 29.1B | SAR 265.51 | 1.02% up | 8% down | ||
| 39 | Cogent BiosciencesCOGT · Health Care | SAR 2.4B | SAR 18.4B | SAR 105.52 | 1.01% up | 20% down | ||
| 40 | Protagonist TherapeuticsPTGX · Health Care | SAR 2.3B | SAR 30.5B | SAR 467.15 | 0.10% down | 46% up | ||
| 41 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 2.3B | SAR 36.7B | SAR 1,579.64 | 0.20% down | 24% down | ||
| 42 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | SAR 2.1B | SAR 27.9B | SAR 355.43 | 0.37% down | 126% up | ||
| 43 | Edgewise TherapeuticsEWTX · Health Care | SAR 2B | SAR 17.4B | SAR 158.67 | 0.62% up | 88% up | ||
| 44 | ABIVAXABVX · Health Care | SAR 1.9B | SAR 27.3B | SAR 311.33 | 1.10% up | 27% down | ||
| 45 | Dianthus TherapeuticsDNTH · Health Care | SAR 1.9B | SAR 18B | SAR 319.17 | 2.17% down | 113% up | ||
| 46 | Ionis PharmaceuticalsIONS · Health Care | SAR 1.8B | SAR 16.7B | SAR 100.36 | 0.76% down | 64% down | ||
| 47 | Oruka TherapeuticsORKA · Health Care | SAR 1.8B | SAR 24.4B | SAR 359.80 | 0.42% down | 241% up | ||
| 48 | Arrowhead PharmaceuticalsARWR · Health Care | SAR 1.7B | SAR 22.7B | SAR 160.47 | 0.49% down | 10% up | ||
| 49 | Definium TherapeuticsDFTX · Health Care | SAR 1.2B | SAR 15B | SAR 109.53 | 0.61% down | 169% up | ||
| 50 | ErascaERAS · Health Care | SAR 1.2B | SAR 18.4B | SAR 52.36 | 0.50% up | 403% up | ||
| 51 | Mirum PharmaceuticalsMIRM · Health Care | SAR 1.2B | SAR 22.4B | SAR 343.33 | 0.46% down | 31% up | ||
| 52 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 521.6M | SAR 30.1B | SAR 434.07 | 0.76% down | 13% up | ||
| 53 | Travere TherapeuticsTVTX · Health Care | SAR 430.7M | SAR 18.2B | SAR 189.97 | 0.89% down | 44% up | ||
| 54 | Axsome TherapeuticsAXSM · Health Care | SAR 331.2M | SAR 26.9B | SAR 512.01 | 0.40% up | 7% down | ||
| 55 | Amneal PharmaceuticalsAMRX · Health Care | -SAR 265.5M | SAR 27.6B | SAR 79.22 | 0.00% | 83% up | ||
| 56 | VeradermicsMANE · Health Care | -SAR 453.9M | SAR 20B | SAR 474.37 | 0.46% up | 233% up | ||
| 57 | Ascendis PharmaASND · Health Care | -SAR 677.6M | SAR 66.1B | SAR 1,007.01 | 1.00% down | 28% up | ||
| 58 | PTC TherapeuticsPTCT · Health Care | -SAR 770.1M | SAR 18.8B | SAR 224.53 | 0.83% down | 20% down | ||
| 59 | CytokineticsCYTK · Health Care | -SAR 2.5B | SAR 27.1B | SAR 194.68 | 0.48% up | 20% down | ||
| 60 | BridgeBio PharmaBBIO · Health Care | -SAR 7.8B | SAR 55.9B | SAR 286.95 | 0.39% down | 17% up | ||
| 61 | AbbVieABBV · Health Care | -SAR 12.3B | SAR 1.92T | SAR 1,087.41 | 1.01% down | 26% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which pharmaceuticals rank first by net assets?
Pfizer (SAR 324.4B), Johnson & Johnson (SAR 305.9B) and Sanofi (SAR 297.1B) are the top three of the 61 pharmaceuticals ranked by net assets as of 18 Nov 2026, 14:31 UTC.
How many pharmaceuticals are in this ranking?
61 are ranked by net assets.
What are these pharmaceuticals worth together?
The 61 pharmaceuticals ranked by net assets have a combined market value of SAR 19.19T as of 18 Nov 2026, 14:31 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.